DJIA 17,826.30 -279.47 -1.54%
NASDAQ 4,931.82 -75.98 -1.52%
S&P 500 2,081.18 -23.81 -1.13%
market minute promo

Ophthotec (NASDAQ: OPHT)

50.57 -1.23 (-2.37%)

Quote as of


company name or ticker

Recent Quotes

OPHT $50.57 -2.37%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $51.23
Previous Close $51.80
Daily Range $50.00 - $51.23
52-Week Range $30.17 - $58.29
Market Cap $1.7B
P/E Ratio -17.56
Dividend (Yield) $0.00 (0.0%)
Volume 222,048
Average Daily Volume 274,760
Current FY EPS -$3.08

Sector

Industry

Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website: http://www.ophthotechinc.com/

News & Commentary Rss Feed

3 Little-Known Biotechs Working On Potential Blockbusters

These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.

AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog

3 Little-Known Stocks I'm Glad I Bought

Ophthotech Corp, Portola Pharmaceuticals Inc., and Insys Therapeutics Inc., have been top performers this past year.

2 Tiny Biotechs That Could Have Blockbuster Opportunity

Got risk tolerance? Check out these two small cap biotechs with huge potential.

Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog

Ophthotech's (OPHT) CEO Dr. David Guyer on Q4 2014 Results - Earnings Call Transcript

Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog

Can These Three BioTech Companies Make It Big?

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog

Benzinga's Top Initiations

See More OPHT News...